Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
- 3 July 2008
- journal article
- research article
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 27 (6) , 692-698
Abstract
5-Fluorouracil (5FU) and capecitabine are two of the most frequently prescribed chemotherapeutic drugs for the treatment of patients with cancer. Administration of test doses of 5FU to eight patients heterozygous for the IVS14+1G > A mutation and five control patients showed that the AUC and clearance were weak parameters with respect to the identification of patients with a DPD deficiency. However, highly significant differences were observed for the terminal half life of 5FU between DPD patients and controls. Thus, a DPD deficiency could be predicted from 5FU blood concentrations measured after the administration of a test dose of 5FU.Keywords
This publication has 22 references indexed in Scilit:
- 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiencyCancer Letters, 2007
- Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceMolecular Cancer Therapeutics, 2006
- Capecitabine as Adjuvant Treatment for Stage III Colon CancerNew England Journal of Medicine, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and PharmacogenomicsPharmacogenomics, 2002
- Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD geneBritish Journal of Cancer, 2002
- Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsAnnals of Oncology, 2001
- Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiencyHuman Genetics, 1999
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999